OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Sandra Naaman, George L. Bakris
Diabetes Care (2023) Vol. 46, Iss. 9, pp. 1574-1586
Open Access | Times Cited: 106
Sandra Naaman, George L. Bakris
Diabetes Care (2023) Vol. 46, Iss. 9, pp. 1574-1586
Open Access | Times Cited: 106
Showing 1-25 of 106 citing articles:
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Vlado Perkovic, Katherine R. Tuttle, Peter Rossing, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 2, pp. 109-121
Closed Access | Times Cited: 428
Vlado Perkovic, Katherine R. Tuttle, Peter Rossing, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 2, pp. 109-121
Closed Access | Times Cited: 428
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
Brendon L. Neuen, Hiddo J.L. Heerspink, Priya Vart, et al.
Circulation (2023) Vol. 149, Iss. 6, pp. 450-462
Open Access | Times Cited: 91
Brendon L. Neuen, Hiddo J.L. Heerspink, Priya Vart, et al.
Circulation (2023) Vol. 149, Iss. 6, pp. 450-462
Open Access | Times Cited: 91
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
Johannes F.E. Mann, Peter Rossing, George L. Bakris, et al.
Nature Medicine (2024) Vol. 30, Iss. 10, pp. 2849-2856
Open Access | Times Cited: 54
Johannes F.E. Mann, Peter Rossing, George L. Bakris, et al.
Nature Medicine (2024) Vol. 30, Iss. 10, pp. 2849-2856
Open Access | Times Cited: 54
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes
Muthiah Vaduganathan, Gerasimos Filippatos, Brian Claggett, et al.
Nature Medicine (2024) Vol. 30, Iss. 12, pp. 3758-3764
Open Access | Times Cited: 27
Muthiah Vaduganathan, Gerasimos Filippatos, Brian Claggett, et al.
Nature Medicine (2024) Vol. 30, Iss. 12, pp. 3758-3764
Open Access | Times Cited: 27
Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
Na Wang, Chun Zhang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3086-3086
Open Access | Times Cited: 22
Na Wang, Chun Zhang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3086-3086
Open Access | Times Cited: 22
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Yehuda Handelsman, John E. Anderson, George L. Bakris, et al.
Metabolism (2024) Vol. 159, pp. 155931-155931
Open Access | Times Cited: 17
Yehuda Handelsman, John E. Anderson, George L. Bakris, et al.
Metabolism (2024) Vol. 159, pp. 155931-155931
Open Access | Times Cited: 17
Targeting the NF-κB p65-MMP28 axis: Wogonoside as a novel therapeutic agent for attenuating podocyte injury in diabetic nephropathy
Xiandeng Li, Shuyan Zhao, Jing Xie, et al.
Phytomedicine (2025) Vol. 138, pp. 156406-156406
Open Access | Times Cited: 2
Xiandeng Li, Shuyan Zhao, Jing Xie, et al.
Phytomedicine (2025) Vol. 138, pp. 156406-156406
Open Access | Times Cited: 2
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
Alessio Mazzieri, Francesca Porcellati, Francesca Timio, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3969-3969
Open Access | Times Cited: 13
Alessio Mazzieri, Francesca Porcellati, Francesca Timio, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3969-3969
Open Access | Times Cited: 13
ACSF2 and lysine lactylation contribute to renal tubule injury in diabetes
Jingfang Chen, Qi Feng, Yingjin Qiao, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1429-1443
Closed Access | Times Cited: 8
Jingfang Chen, Qi Feng, Yingjin Qiao, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1429-1443
Closed Access | Times Cited: 8
Phenylsulfate-induced oxidative stress and mitochondrial dysfunction in podocytes are ameliorated by Astragaloside IV activation of the SIRT1/PGC1α /Nrf1 signaling pathway
Liu Li, Junju Zou, Hui Zhou, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117008-117008
Open Access | Times Cited: 8
Liu Li, Junju Zou, Hui Zhou, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117008-117008
Open Access | Times Cited: 8
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
Kenneth W. Mahaffey, Katherine R. Tuttle, Mustafa Arici, et al.
European Heart Journal (2024)
Open Access | Times Cited: 8
Kenneth W. Mahaffey, Katherine R. Tuttle, Mustafa Arici, et al.
European Heart Journal (2024)
Open Access | Times Cited: 8
Single-cell atlas reveals multi-faced responses of losartan on tubular mitochondria in diabetic kidney disease
Zhen Zhu, Guangxin Luan, Song Wu, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Zhen Zhu, Guangxin Luan, Song Wu, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
The regulatory role of miRNA and lncRNA on autophagy in diabetic nephropathy
Siming Yu, Yue Li, Xinxin Lu, et al.
Cellular Signalling (2024) Vol. 118, pp. 111144-111144
Closed Access | Times Cited: 7
Siming Yu, Yue Li, Xinxin Lu, et al.
Cellular Signalling (2024) Vol. 118, pp. 111144-111144
Closed Access | Times Cited: 7
Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
Peter Rossing, Tine W. Hansen, Thomas Kümler
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S6, pp. 13-21
Open Access | Times Cited: 5
Peter Rossing, Tine W. Hansen, Thomas Kümler
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S6, pp. 13-21
Open Access | Times Cited: 5
Preventing diabetes complications
Sophie Templer, Sarah Abdo, Tang Wong
Internal Medicine Journal (2024) Vol. 54, Iss. 8, pp. 1264-1274
Closed Access | Times Cited: 5
Sophie Templer, Sarah Abdo, Tang Wong
Internal Medicine Journal (2024) Vol. 54, Iss. 8, pp. 1264-1274
Closed Access | Times Cited: 5
The efficacy and safety of Ginkgo biloba L. leaves extract combined with ACEI/ARB on diabetic kidney disease: a systematic review and meta-analysis of 41 randomized controlled trials
Zehua Zhang, Shiyun Tang, Shiyu Liu, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Zehua Zhang, Shiyun Tang, Shiyu Liu, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
PREVENTING DIABETIC KIDNEY DISEASE: A SYSTEMATIC REVIEW OF CURRENT PHARMACOLOGICAL APPROACHES
B Dharani, STEPHY SEBASTIAN, Shermin Nazrin, et al.
International Journal of Applied Pharmaceutics (2025), pp. 68-81
Open Access
B Dharani, STEPHY SEBASTIAN, Shermin Nazrin, et al.
International Journal of Applied Pharmaceutics (2025), pp. 68-81
Open Access
Alpiniae oxyphyllae Fructus ameliorates renal lipid accumulation in diabetic kidney disease via activating PPARα
Zijie Yan, Lin Zhang, Xingmin Han, et al.
Asian Pacific Journal of Tropical Biomedicine (2025) Vol. 15, Iss. 1, pp. 11-23
Open Access
Zijie Yan, Lin Zhang, Xingmin Han, et al.
Asian Pacific Journal of Tropical Biomedicine (2025) Vol. 15, Iss. 1, pp. 11-23
Open Access
Is activated Yes-Associated Protein (YAP) associated with renal damage in type2 diabetic nephropathy?
Ahmed Waheed Kashif, Raghav Sharma, Sudeep Prakash, et al.
Medical Journal Armed Forces India (2025)
Closed Access
Ahmed Waheed Kashif, Raghav Sharma, Sudeep Prakash, et al.
Medical Journal Armed Forces India (2025)
Closed Access
Machine learning-driven Raman spectroscopy: A novel approach to lipid profiling in diabetic kidney disease
Adrianna Kryska, Magdalena Sawic, Joanna Depciuch, et al.
Nanomedicine Nanotechnology Biology and Medicine (2025), pp. 102804-102804
Open Access
Adrianna Kryska, Magdalena Sawic, Joanna Depciuch, et al.
Nanomedicine Nanotechnology Biology and Medicine (2025), pp. 102804-102804
Open Access
GLP-1-Rezeptor-Agonist mit Turbo – zukünftige Entwicklung in der Therapie der chronischen Nierenerkrankung bei Diabetes mellitus
Bernhard M. W. Schmidt
Deleted Journal (2025)
Closed Access
Bernhard M. W. Schmidt
Deleted Journal (2025)
Closed Access
Untargeted metabolomic and proteomic analysis implicates SIRT2 as a novel therapeutic target for diabetic nephropathy
Ruijing Zhang, Runze Chang, Heng Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Ruijing Zhang, Runze Chang, Heng Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Inhibiting Tgf-Β1/ Smad Pathways by Targeting Acsl4 /Gpx4 Axis Dependent Ferroptosis Attenuates Diabetic Renal Fibrosis
Zhihua Wu, Ting Yu, Lin Yan, et al.
(2025)
Closed Access
Zhihua Wu, Ting Yu, Lin Yan, et al.
(2025)
Closed Access
The Role and Mechanism of Gut Microbiota in the Development of Diabetic Nephropathy
梅 韩
Advances in Clinical Medicine (2025) Vol. 15, Iss. 02, pp. 215-222
Closed Access
梅 韩
Advances in Clinical Medicine (2025) Vol. 15, Iss. 02, pp. 215-222
Closed Access
Empagliflozin attenuates renal damage in diabetic nephropathy by modulating mitochondrial quality control via Prdx3-PINK1 pathway
Canghui Guo, Tao Zhang, Lingyu Du, et al.
Biochemical Pharmacology (2025) Vol. 235, pp. 116821-116821
Open Access
Canghui Guo, Tao Zhang, Lingyu Du, et al.
Biochemical Pharmacology (2025) Vol. 235, pp. 116821-116821
Open Access
